Under a revamped executive team and board of directors the company says its now diving deeper into research areas like immunology and rare diseases. To that end Biogen in September completed the 7 billion acquisition of Reata Pharmaceuticals  which gave it a newtomarket Friedreichs ataxia. That drug called Skyclarys is off to a strong start according to RBCs Abrahams